Press releases
- Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
- Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
- Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
- Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
- Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
- Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- Carisma Therapeutics to Present at Upcoming Conferences
More ▼
Key statistics
On Friday, Carisma Therapeutics Inc (W2J:STU) closed at 1.06, 9.48% above its 52-week low of 0.97, set on Jun 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.06 |
---|---|
High | 1.07 |
Low | 1.06 |
Bid | 1.03 |
Offer | 1.10 |
Previous close | 1.08 |
Average volume | 3.56 |
---|---|
Shares outstanding | 41.54m |
Free float | 28.18m |
P/E (TTM) | -- |
Market cap | 47.36m USD |
EPS (TTM) | -2.01 USD |
Data delayed at least 15 minutes, as of Jun 14 2024.
More ▼